You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

94 search results for: mechanism of disease

<b>Disease</b>-Specific Aspects <b>of</b> Itch in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Disease</b>s with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic <b>Disease</b>s and Psychiatric Conditions

expert video

PN is Considered a Unique Clinical Entity Distinct from Other Pruritic Diseases and Psychiatric Conditions

2 min

Dermatology

Dr. Sarina Elmariah discusses PN being a unique clinical entity, distinct from other pruritic diseases and psychiatric conditions.

The Potential Impact <b>of</b> Early Intervention in Atopic Dermatitis in Children

expert video

The Potential Impact of Early Intervention in Atopic Dermatitis in Children

2 min

Dermatology

Dr. Amy Paller shares her opinion of whether treatment is needed when children might outgrow their disease.

Emerging Understanding <b>of</b> Chronic Itchy Skin <b>Disease</b>s – Shared and Unique Drivers in AD, PN, and CSU

Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

5 min

Dermatology

An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.

Expert Case Series: What is the Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

interactivity

Expert Case Series: What is the Role of Type 2 Inflammation in Skin Barrier Dysfunction Commonly Observed in Atopic Dermatitis?

10 min

Dermatology

Gain insights with Prof. Lisa Beck: Explore the link between skin barrier dysfunction and type 2 inflammation in atopic dermatitis.

Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in Atopic Dermatitis Interview

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

Importance <b>of</b> Barrier Dysfunction in Driving AD Pathophysiology

expert video

Importance of Barrier Dysfunction in Driving AD Pathophysiology

22 min

Dermatology

The impact of type 2 inflammation on components of the skin barrier driving atopic dermatitis – a presentation from the ADVENT symposium at ISID 2023.

UCARE 2023: Role <b>of</b> Type 2 Inflammation in CSU Pathogenesis

expert video

UCARE 2023: Role of Type 2 Inflammation in CSU Pathogenesis

7 min

Dermatology

Dr. Saini provides a deep dive into the pathophysiology of type 2 inflammation in CSU.

The Role <b>of</b> Type 2 Inflammation in Atopic Dermatitis

expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

1 min

Dermatology

The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD

expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

14 min

Dermatology

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in AD

expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

26 min

Type 2 Inflammation

Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Costa RicaChange country/region